BACKGROUND
• Flucloxacillin is a semi-synthetic penicillin, widely used for the management of soft-tissue infections has been associated with druginduced liver injury (DILI)
• A recent study using genome-wide association (GWA) methods identified the presence of the HLA-B*5701 allele to be associated with a high risk of DILI (odds ratio= 80.6, P=8.7 x10 -33 ) 1 with the conclusion that HLA-B*5701 may be the main genetic risk factor for flucloxacillininduced liver injury
• HLA-B*5701 screening is routinely performed to identify HIV-infected individuals at risk of hypersensitivity reaction (HSR) to the antiretroviral drug, abacavir. As a result, HLA-B*5701 testing is now a routine part of care in many HIV clinics
• Given the high prevalence of soft-tissue infections in HIV-1 positive patients, we investigated whether flucloxacillin use was associated with adverse events in a cohort of HIV-infected individuals known to be HLA-B*5701 positive.
RESULTS (2):
• After reviewing all available clinical and laboratory information, no case of suspected or confirmed clinical or biochemical toxicities within 1-90 days after prescription of flucloxacillin were identified
• Liver function tests were within normal limits apart from in the one case with HCV infection, in which ALT before and after the 90 days of observation remained above 60(IU/l)
• The interval of 1 -90 days after prescription was chosen because of the characteristic clinical picture of flucloxacillin-DILI described in clinical reports of liver disease associated with flucloxacillin
METHODS
• Clinical and pharmacological prospective databases from HIVinfected patients attending the HIV department at St Mary's Hospital in London were used to identify individuals who had tested positive for the HLA-B*5701 allele using a commercial polymerase chain reaction assay (Lab21 Ltd., Cambridge, UK) between January 2008 and July 2012
• Clinical and laboratory parameters such as alanine aminotransferase (ALT), bilirubin and alkaline phosphatase (Alk Phos) were assessed in those individuals with a positive HLA-B*5701 test who had a documented course of flucloxacillin during the study period 
DISCUSSION
• Despite the recently reported association between HLA-B*5071 and flucloxacillin DILI from a case control study 1 , we found no evidence of liver toxicity in a small sample of HIV-infected patients treated with flucloxacillin and carrying both the HLA-B*5701 allele and receiving flucloxacillin.
• Although these data suggest that there may not be a major risk to HIV patients in routine practice, a note of caution needs to be added. Firstly, age over 55 years old, female sex and a treatment duration longer than 14 days have been proposed as risk factors for flucloxacillin DILI 2 . In this study, all patients were below the age of 55 years, only one was a woman and none had more than 14 days of flucloxacillin therapy. Therefore is not possible to conclude that having a HLA-B*5071 genotype is not associated with flucloxacillin DILI in all HIV-1 positive individuals.
• It remains crucial for clinicians to be aware of the association of HLA-B*5701 with DILI, particularly in elderly patients, those with underlying liver disease and those requiring prolonged antibiotic therapy.
• • We identified 79 individuals who had tested positive for the HLA B*5701. In total 10 of 79 (12.7%) had received flucloxacillin during the study period
• In all cases, flucloxacillin was prescribed for uncomplicated soft-tissue infections. The median total dose and duration of treatment were 20 gr (range 10 -28 g) and 10 days (range 5 -14 days), respectively.
